ONJ With Bone-Modifying Agents in Breast Cancer Patients

Share this post

Osteonecrosis of the jaw was reported in metastatic breast cancer patients treated with bone-modifying agents; the incidence was higher with denosumab compared with bisphosphonates.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply